PROGRAMME EHMSG Workshop
Friday, September 9, 2022
08.25 – 08.30 hrs Welcome by EHMSG President Georgina Hold
08.30 – 09.30 hrs Session 1 - Introductory Lectures
Chair: Georgina Hold, Australia & Colm O’Morain, Ireland & Anthony Axon, United Kingdom
08.30 - 09.00
Role of H. pylori at the gastro-esophageal junction
Ken McColl, Glasgow, United Kingdom
09.00 - 09.30
Dialogue between H. pylori and the gut microbiota
Emad El Omar, Sydney, Australia
09.30 – 11.00 hrs Session 2 - Maastricht VI
Chair: Peter Malfertheiner, Germany & Richard Hunt, Canada/United Kingdom
09.30 - 09.42
The consensus concept
Peter Malfertheiner, Munich, Germany
09.42 - 09.54
H. pylori infection in gastroduodenal and extragastric diseases
Theodore Rokkas, Athens, Greece
09.54 - 10.06
New Demands in H. pylori diagnosis
Francis Mégraud, Bordeaux, France
10.06 - 10.18
Therapy of H. pylori infection in evolution
Javier Gisbert, Madrid, Spain
10.18 - 10.30
H. pylori screening in the prevention medicine
Jhy Ming Liou, Taipei, Taiwan
10.30 - 10.42
H. pylori in the relationship with other gastric microbiota
Antonio Gasbarrini, Rome, Italy
10.42 - 10.54
H. pylori treatment and the impact on gut microbiota
Christian Schulz, Munich, Germany
11.00 - 11.30 hrs Coffee Break
11.30 – 13.00 Session 3 - Gastric carcinogenesis
Chair: José Machado, Portugal & Jung Hwoon-Yong, Ulsan, South Korea
11.30 - 11.50
The human stomach epithelial homeostasis recapitulated in-vitro by using mucosoid cultures
Francesco Boccellato, Oxford, UK
11.50 - 12.10
Utility of preclinical models to understand carcinogenesis
Michael Sigal, Berlin, Germany
12.10 - 12.30
Autophagy is necessary for gastric cancer stem cell emergence
Emilie Bessede, Bordeaux, France
12.30 - 12.50
Autoimmune atrophic gastritis and gastric cancer
Marino Venerito, Magdeburg, Germany
13.00 – 14.00 hrs Lunch Break & Poster Viewing
14.00 – 15.40 hrs Session 4 - Microbiota
Chair: Richard Hansen, United Kingdom & Jae Gyu Kim, Seoul, South Korea
14.00 - 14.20
Gastric microbiota transplantation recapitulates premalignant lesions in germ-free mice
Yong-Chang Lee, Seoul, Korea
14.20 - 14.40
Establishment of gut microbiota in humans
Hakdong Shin, Seoul, Korea
14.40 - 15.00
Use of registers in microbiota research
Nele Brusselaers, Stockholm, Sweden
15.00 - 15.20
Bidirectional crosstalk between mucins and the microbiota at the level of the GI epithelium
Annemieke Smet, Antwerp, Belgium
15.20 - 15.40
New microbiota therapeutics
Harry Sokol, Paris, France
15.45 – 17.15 hrs Session 5 - Parallel Workshops from Submitted Abstracts W1
Microbiota in Health and Disease
Chair: Georgina Hold, Sydney, Australia & Antonio Gasbarrini, Rome, Italy
15.45 – 16.00
Aging and shared household are the main determinant of the gut microbial similarity in twins
Alexander Link, Magdeburg, Germany
16.00 – 16.15
Whole Metagenome Shotgun Sequencing as a Next-Generation Sequencing Approach to Characterize the Taxonomy and Functional Risk Factors of the Gastric Microbiome
Anthony Mannion, Cambridge, United States
16.15 – 16.30
Implementation of a metatranscriptomics strategy for functional profiling of the gastric cancer microbiome
Rui Ferreira, Porto, Portugal
16.30 – 16.45
Relationships of the gut microbiome with cognitive development among healthy school age children
Khitam Muhsen, Tel Aviv, Israel
16.45 – 17.00
Association of stomach microbiome with prognosis of gastric cancer patients
Konrad Lehr, Magdeburg, Germany
17.00 – 17.15
Microbiome signature of metabolically healthy obese individuals according to anthropometric, metabolic and inflammatory parameters
Nam-Eun Kim, Seoungnam-si, Republic of Korea
15.45 – 17.15 hrs Session 6 - Parallel Workshops from Submitted Abstracts W2
Diagnosis, Epidemiology, Extragastric Disease
Chair: Stella Smith, Lagos, Nigeria & Francis Mégraud, Bordeaux, France
15.45 – 16.00
Helicobacter pylori outer membrane vesicles alter astrocyte and neuronal function in vitro and in vivo
Manuel Valenzuela-Valderrama, Santiago, Chile
16.00 – 16.15
Neurotoxic properties of Helicobacter pylori urease: a possible link to Alzheimer’s Disease?
Celia Carlini, Porto Alegre, Brazil
16.15 – 16.30
Helicobacter pylori diagnostic tests used in 35,000 patients in Europe: results from the European Registry on H. pylori Management (Hp-EuReg)
Laimas Jonaitis, Kaunas, Lithuania
16.30 – 16.45
Real-time assessment of H. pylori gastritis guided by Endofaster: a prospective cohort study.
Riccardo Vasapolli, Munich, Germany
16.45 – 17.00
Prevalence of and risk factors for familial Helicobacter pyloriinfection in China: a nationwide family-based cross-sectional study
Xianzhu Zhou, Shanghai, China
17.00 – 17.15
High incidence of resistance to antibiotics used for eradication of Helicobacter pyloriin the UK
Suffi Suffian, NOTTINGHAM, United Kingdom
17.15 – 17.45 hrs Coffee Break
17.45 – 19.15 hrs Session 7 - Parallel Workshops from Submitted Abstracts W3
Pathogenesis of Helicobacter pylori
Chair: Ari Ristimäki, Helsinki, Finland & Mark Pritchard, Liverpool, United Kingdom
17.45 – 18.00
Single-cell transcriptomics atlas of Helicobacter pylori infection-associated gastric carcinogenesis
Nianshuang Li, Nanchang, China
18.00 – 18.15
The cytolethal distending toxin modulates cell differentiation and elicits epithelial to mesenchymal transition
Lamia Azzi-Martin, Bordeaux, France
18.15 – 18.30
Effects of chronic Helicobacter pylori strain PMSS1 infection on whole brain and gastric iron homeostatsis in male INS-GAS mice
Hilda Holcombe, Cambridge, United States
18.30 – 18.45
CD40-CD40L blockade attenuates disease in a new mouse model of gastric B cell MALT lymphoma
Richard Ferrero, Victoria, Australia
18.45 – 19.00
Th1 cytokines, especially TNF, cause NF-κB2 dependent morphological changes in primary mouse gastric organoids (gastroids)
Liwen Liu, Liverpool, United Kingdom
19.00 – 19.15
ACE2 is involved in the carcinogenic process of Helicobacter pylori infection
Huan Wang, Nanchang, China
17.45 – 19.15 hrs Session 8 - Parallel Workshops from Submitted Abstracts W4
Treatment of Helicobacter pylori
Chair: Jan Bornschein, Oxford, United Kingdom & Francesco Franceschi, Rome, Italy
17.45 – 18.00
Mistakes in empirical eradication therapies for Helicobacter pylori in 45,778 patients: data from the European Registry on H. pylori management (Hp-EuReg)
Samuel J. Martínez-Domínguez, Zaragoza, Spain
18.00 – 18.15
H. pylori phages: from genome release to hope for use as therapy
Rute Ferreira, Braga, Portugal
18.15 – 18.30
Long-term changes of gut microbiota and antibiotic resistome after H. pylori eradication- a multicenter randomized trial
Jyh-Ming Liou, Taipei, Taiwan
18.30 – 18.45
Comparison of empirical first-line treatment between tegoprazan versus lansoprazole based quadruple therapy: double-blind randomized controlled trial
Jun-Won Chung, Incheon, Republic of Korea
18.45 – 19.00
Comparison of the effectiveness of Helicobacter pylori eradication regimens between the elderly and non-elderly populations: data from the European Registry on H. pylori management (Hp-EuReg)
Paulius Jonaitis, Kaunas, Lithuania
19.00 – 19.15
Pilot studies of Vonoprazan-containing Helicobacter pylori eradication therapy
Sarita Ratana-Amornpin, Pathumthani, Thailand
20.00 hrs Networking Dinner
Saturday, September 10, 2022
08.00 – 09.30 hrs Session 9 - Fecal Microbiota Transplantation (FMT)
Chair: Josbert Keller, Den Haag, The Netherlands, Christian Hvas, Aarhus, Denmark
08.00 - 08.05
Introduction: FMT: from C. difficile towards other indications
Josbert Keller, Leiden, The Netherlands
08.05 - 08.25
FMT and immunotherapy: to overcome resistance and to treat immunotherapy induced colitis
Gianluca Ianiro, Rome, Italy
08.25 - 08.40
FMT for Inflammatory Bowel diseases: timing and selection of patients and donors
Tariq Iqbal, Birmingham, United Kingdom
08.40 - 09.00
Encapsulation, life bacterial products and regulation
Christian Hvas, Aarhus, Denmark
09.00 - 09.15
Introduction of an FMT registry
Maria Vehreschild, Frankfurt, Germany
09.15 - 09.30
Investigations of serious adverse events after FMT
Liz Terveer, Leiden, The Netherlands
09.30 – 10.00 hrs Coffee Break
10.00 – 11.20 hrs Session 10 - H. pylori diagnosis & treatment
Chair: Theodore Rokkas, Athens, Greece & Jong-Jae Park, Seoul, South Korea
10.00 - 10.20
New methods for antimicrobial susceptibility testing. The US experience
David Graham, Houston, Texas, USA
10.20 - 10.40
H. pylori rescue treatment. Data from the Hp-EuReg
Olga Nyssen, Madrid, Spain
10.40 - 11.00
Use of serum pepsinogen assays in clinical practice
Sun-Young Lee, Seoul, Korea
11.00 - 11.20
Impact of probiotics on the faecal resistome during H. pylori eradication
Marcis Leja, Riga, Latvia
11.20 – 12.20 hrs Session 11 - Industry-Sponsored Satellite Symposium
Click here for more information
Chair: Colm O’Morain, Dublin, Ireland
12.20 – 13.20 hrs Lunch Break & Poster Viewing
13.20 – 14.50 hrs Session 12 - Parallel Workshops from Submitted Abstracts W5
Microbiota Manipulation
Chair: Giovanni Gasbarrini, Rome, Italy & Richard Hansen, Glasgow, United Kingdom
13.20 – 13.35
Effects of transplant dose, route of administration, and repeating on the outcome of fecal microbiota transplantation for patients with irritable bowel syndrome
Magdy El-Salhy, Bergen, Norway
13.35 – 13.50
The effect of multi-strain probiotics on diarrhea in patients with type 2 diabetes and metformin intolerance
Katarzyna Nabrdalik, Zabrze, Poland
13.50 – 14.05
A microbiota targeted, Mediterranean diet-based nutritional education program positively modifies the intestinal microenvironment of healthy individuals
Tsachi Perets, Petah Tikva, Israel
14.05 – 14.20
Fecal microbiota transplantation (FMT) on irritable bowel syndrome (IBS): A randomized, placebo-controlled, double-blind study
Natsuda Aumpan, Pathumthani, Thailand
14.20 – 14.35
Immune and non immune changes following fecal microbiota transplantation in experimental colitis: emerging pathways of fmt derived mucosal healing
Valentina Petito, Rome, Italy
14.35 – 14.50
Changes in gut microbiota after antibacterial therapy among children: preliminary data
Ilva Daugule, Riga, Latvia
13.20 – 14.50 hrs Session 13 - Parallel Workshops from Submitted Abstracts W6
Gastric Carcinogenesis
Chair: Yaron Niv, Pardesia, Israel & Karen Robinson, Nottingham, United Kingdom
13.20 – 13.35
Optimal Follow-Up Period after Endoscopic Resection of Early Gastric Cancer: A Multi-Center Retrospective Cohort Study
Byung-Wook Kim, Incheon, Republic of Korea
13.35 – 13.50
Atrophic gastritis and gastric cancer tissue miRNome analysis
Ruta Inciuraite, Kaunas, Lithuania
13.50 – 14.05
Helicobacter pylori testing among individuals at risk of gastric cancer: a potential interception point to reduce the gastric cancer burden in the US
Meira Epplein, Durham, United States
14.05 – 14.20
Incidence of gastric cancer among long-term users of proton pump inhibitors after Helicobacter pylori eradication; a population-based cohort study in Korea
Jong Wook Kim, Goyang, Republic of Korea
14.20 – 14.35
Identification of serological markers associated with gastric cancer in two Chinese studies using Helicobacter pylori multi-strain microarrays
Rima Jeske, Heidelberg, Germany
14.35 – 14.50
Distinct mucin-microbiome signatures in patients with gastric cancer
Baptiste Oosterlinck, Antwerp, Belgium
14.50 – 15.20 hrs Coffee Break
15.20 – 16.20 hrs Session 14 - Potassium Competitive Acid Blockers (P-CABs)
Chair: Kenneth McColl, Glasgow, United Kingdom & Javier Gisbert, Madrid, Spain
15.20 - 15.40
P-CAB performance from a network meta-analysis
Theodore Rokkas, Athens, Greece
15.40 - 16.00
Pharmacological and clinical properties of P-CABs
Colin Howden, Memphis, TN, USA
16.00 - 16.20
Long-term experience with P-CABs
Ken Sugano, Shimotsuke City, Japan
16.20 – 17.00 hrs Session 15 - State of the Art lectures: Looking to the future
Chair: Lars Engstrand, Stockholm, Sweden & Marcis Leja, Riga, Latvia
16.20 - 16.40
The BioCyc databases: pathways, omics tools and enhanced genome annotation
Ron Caspi, Menlo Park, CA, USA
16.40 - 17.00
New developments on gastric cancer treatment
Tamara Matysiak, Nantes, France
17.00 – 18.10 hrs Session 16 - Closing Session
Chair: Annemieke Smet, Antwerp, Belgium & Georgina Hold, Sydney, Australia
17.00 - 17.20
The discovery of H. pylori viewed from the UK Cliodna McNulty, Gloucester, UK
17.20 - 17.30
Awarding of the Marshall and Warren Medal 2022 to Massimo Rugge, Padova, Italy
17.30 - 17.40
Awarding of the Marshall and Warren Medal 2020 to Hazel Mitchell & 2021 to Dulciene Queiroz
17.40 - 17.50
Awarding of the EHMSG Oral and Poster Awards
17.50 - 18.00
Presentation of the EHMSG Journal
18.00 - 18.10
Presentation of the next meeting in Antwerp
Annemieke Smet, Antwerp, Belgium
Closing Remarks